New York, Jan 9, 2026, 13:11 EST — Regular session
- Oddity Tech shares slid about 6% in afternoon trading.
- A regulatory filing disclosed the departure of Oddity Labs’ chief science officer; the company said it does not expect an impact on outlook.
- KeyBanc cut its price target on the stock to $50 from $70 while keeping an Overweight rating.
Oddity Tech Ltd shares fell 5.8% to $36.28 on Friday, extending a sharp pullback for the beauty and wellness company as investors weighed a senior departure at its research unit and a fresh price-target cut. The stock opened higher but swung between $35.80 and $38.82.
In a Form 6-K filing with U.S. regulators — a report foreign-listed companies use to disclose material updates — Oddity said Dr. Ido Bachelet is no longer employed with the company. Bachelet had served as chief science officer of ODDITY LABS, and his duties have been assumed by other leaders; the company said the change was “not expected to impact” its financial outlook or ongoing product timelines. (ODDITY)
The timing matters because Oddity has sold investors on multiple growth engines beyond its core online brands, with ODDITY LABS and new initiatives a key part of the pitch. In November, CEO Oran Holtzman said the company would “continue to invest in new brands, ODDITY Labs, and tech innovation,” as it raised its full-year 2025 outlook to net revenue of $806 million to $809 million and adjusted diluted EPS of $2.10 to $2.12. (ODDITY)
Adding to the pressure, KeyBanc lowered its price target on Oddity to $50 from $70 and kept an Overweight rating, TipRanks reported, citing TheFly. A price target is an analyst’s estimate of where a stock could trade over the next year; “Overweight” typically signals the analyst expects the stock to outperform peers. (TipRanks)
The move in Oddity stood out against a mixed tape for beauty names. e.l.f. Beauty fell 0.6%, while Ulta Beauty rose 1.2% and Coty added 0.6%.
Oddity, an Israel-based group, runs digital-first brands in beauty and wellness and sells products largely through its online platform, using data and algorithms to match customers with offerings. (MarketScreener)
But leadership changes at a science-heavy unit can still rattle a stock even when the company says day-to-day work carries on, especially ahead of a results update when guidance gets tested. Any hint of slower product work, or a miss versus the company’s latest targets, would likely keep pressure on the shares.
What investors watch next is the company’s next earnings date and any detail on the Oddity Labs leadership bench. Nasdaq’s calendar estimates the next report around Feb. 24, though the company has not posted a 2026 event date on its investor site. (Nasdaq)
